ArticleBioengineering (Basel, Switzerland)2020
Challenges and Solutions for Commercial Scale Manufacturing of Allogeneic Pluripotent Stem Cell Products.
Article in Bioengineering (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Assessing mesh size and diffusion of alginate bioinks: A crucial factor for successful bioprinting functional pancreatic islets.Materials today. Bio · 2025Article
- Advancing cell therapies with artificial intelligence and synthetic biology.Current opinion in biomedical engineering · 2025Article
- Expansion of induced pluripotent stem cells under consideration of bioengineering aspects: part 1.Applied microbiology and biotechnology · 2025Article
- Accelerated production of human epithelial organoids in a miniaturized spinning bioreactor.Cell reports methods · 2024Article
- Bridging the Gap: Advances and Challenges in Heart Regeneration from In Vitro to In Vivo Applications.Bioengineering (Basel, Switzerland) · 2024Review
- Stochastic biological system-of-systems modelling for iPSC culture.Communications biology · 2024Article
- Review
- Mesenchymal and induced pluripotent stem cell-based therapeutics: a comparison.Applied microbiology and biotechnology · 2023Review
- Review
- Development of a 48-Well Dynamic Suspension Culture System for Pancreatic Differentiation from Human Embryonic Stem Cells.Stem cell reviews and reports · 2022Article
- Integration of Islet/Beta-Cell Transplants with Host Tissue Using Biomaterial Platforms.Endocrinology · 2020Review
- Stem Cell Bioprocessing and Manufacturing.Bioengineering (Basel, Switzerland) · 2020Article
- Vascularization is the next challenge for skin tissue engineering as a solution for burn management.Burns & trauma · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic cell therapy products, such as therapeutic cells derived from pluripotent stem cells (PSCs), have amazing potential to treat a wide variety of diseases and vast numbers of patients globally. However, there are various challenges related to the manufacturing of PSCs in large enough quantities to meet commercial needs. This manuscript addresses the challenges for the process development of PSCs production in a bioreactor, and also presents a scalable bioreactor technology that can be a possible solution to remove the bottleneck for the large-scale manufacturing of high-quality therapeutic cells derived from PSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.